Novel medicines focused on the BIG Axis

We are advancing innovative therapies across our internal and affiliate pipelines.

 

Our Internal R&D Pipeline

PureTech’s internal programs are focused on harnessing the lymphatic system to treat devastating diseases including lymphatic disorders, intractable cancers, immunological diseases and CNS disorders. The lymphatic system is the central channel for immune cell trafficking, connects all tissues to regional lymph nodes and is essential for fluid balance.

 

LYT-100
Phase: PHASE 1

Lymphedema

LYT-100

PureTech is developing a clinical stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema. LYT-100, an oral small molecule with well-established preclinical anti-fibrotic activity, has been previously studied in a Phase 1 clinical trial in healthy volunteers and was observed to be well tolerated with a favorable pharmacokinetic profile to enable twice daily oral dosing. PureTech will continue clinical development in healthy volunteers, looking at additional safety and pharmacokinetics of LYT-100 prior to initiating a human biomarker proof-of-concept study expected in 2020. 

 

LYT-200 (Immuno-oncology)
Anti-Galectin-9 MAb
Phase: IND-ENABLING
Solid tumors
Expect to File IND
H1 2020

LYT-200

PureTech is developing two first-in-class, fully human antibodies which are aimed at countering fundamental mechanisms of immunosuppression. PureTech’s therapeutic candidates are designed to address cancers that are suboptimally treated with currently available standard of care and immunotherapies because the body’s natural defenses are compromised by persistent tumor immune evasion. These antibodies have the potential to be used as single agents in addition to being used in combinatorial approaches (e.g., with checkpoint inhibitors). These programs are based on the research conducted at Professor George Miller's laboratory and are exclusively licensed by PureTech from NYU School of Medicine. 

LYT-200 is a human IgG4 antibody directed against galectin-9, a global immunosuppressor. Galectin-9 exerts immunosuppression by binding to multiple partners and facilitating a tumor-permissive microenvironment. This antibody has shown excellent physical and functional properties, and exciting proof-of-concept data has been generated in both mouse and human cancer preclinical models.

MORE
LYT-210 (Immuno-oncology)
Anti-Delta-1 MAb
Phase: LEAD OPTIMIZATION
Solid tumors

LYT-210

PureTech is developing two first-in-class, fully human antibodies which are aimed at countering fundamental mechanisms of immunosuppression. PureTech’s therapeutic candidates are designed to address cancers that are suboptimally treated with currently available standard of care and immunotherapies because the body’s natural defenses are compromised by persistent tumor immune evasion. These antibodies have the potential to be used as single agents in addition to being used in combinatorial approaches (e.g., with checkpoint inhibitors). These programs are based on the research conducted at Professor George Miller's laboratory and are exclusively licensed by PureTech from NYU School of Medicine. 

LYT-210 is directed against immunosuppressive γδ T cells which are upregulated in multiple solid tumors and have a distinct phenotype as well as functional properties to make them uniquely targetable in cancer. This antibody has shown excellent physical and functional properties, and exciting proof-of-concept data has been generated in both mouse and human cancer preclinical models.

MORE
Lymphatic Targeting - Milk Exosomes
Phase: DISCOVERY

Lymphatic Targeting - Milk Exosomes

PureTech’s novel milk exosome-based technology may be uniquely positioned to facilitate the oral administration of complex payloads such as nucleic acids, peptides, and small molecules, by harnessing our growing understanding of the biology at the gut-immune interface. Milk exosomes represent a versatile engineerable platform to potentially resolve the long-standing challenge of oral bioavailability of macromolecules and complex small molecules. This technology is based on the research of Professor Ramesh Gupta at University of Louisville, and is exclusively licensed to PureTech. 

MORE
Lymphatic Targeting - Lipid Transport
Phase: DISCOVERY

Lymphatic Targeting - Lipid Transport

PureTech is developing a lymphatic targeting approach that leverages the body’s natural lipid transport mechanisms to substantially enhance the transport of compounds into the lymphatic system from an oral route. Nearly all dietary lipids (such as triglycerides) are absorbed from the small intestine into lymphatic vessels (lacteals), and these vessels transport lipids and immune cells to the mesenteric lymph nodes in the gut before entering systemic circulation. To access this absorption pathway, a triglyceride is reversibly attached to a drug of interest via a linker optimized to release the drug at the site of interest. This technology is based on the research of Professor Christopher Porter at Monash University in Australia and is exclusively licensed to PureTech.

MORE
Brain Lymphatics
Phase: DISCOVERY

Brain Lymphatics

PureTech is pursuing an approach to address neurodegenerative and neuroinflammatory conditions by harnessing the recently discovered lymphatic system in the brain. In July 2018, the foundational science that underlies PureTech’s internal CNS lymphatics technology was published as the cover story in the prestigious scientific journal Nature. The publication revealed that modulation of lymphatic function in the brain may prevent or delay diseases associated with aging, including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and age-associated cognitive decline. An additional Nature Neuroscience publication in September 2018 highlighted the key role of brain lymphatics in neuroinflammatory conditions such as multiple sclerosis. More recently, the role of meningeal lymphatics has been validated by other research groups as a key mediator in the clearance of macromolecules such as tau-related proteins and α-synuclein, from the CNS, which speaks to the potentially important role played by this system in tauopathies and Parkinson’s disease respectively. This technology is based on the research of Professor Jonathan Kipnis at the University of Virginia School of Medicine, and is exclusively licensed to PureTech.

MORE
TRIAL PHASE
PROGRAMDISCOVERYLEAD OPTIMIZATIONIND-ENABLINGPHASE 1PHASE 2PHASE 3 / PIVOTAL
LYT-100
Lymphedema

LYT-100

PureTech is developing a clinical stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema. LYT-100, an oral small molecule with well-established preclinical anti-fibrotic activity, has been previously studied in a Phase 1 clinical trial in healthy volunteers and was observed to be well tolerated with a favorable pharmacokinetic profile to enable twice daily oral dosing. PureTech will continue clinical development in healthy volunteers, looking at additional safety and pharmacokinetics of LYT-100 prior to initiating a human biomarker proof-of-concept study expected in 2020. 

 

LYT-200 (Immuno-oncology)
Anti-Galectin-9 MAb
Solid tumors
Expect to File IND
H1 2020

LYT-200

PureTech is developing two first-in-class, fully human antibodies which are aimed at countering fundamental mechanisms of immunosuppression. PureTech’s therapeutic candidates are designed to address cancers that are suboptimally treated with currently available standard of care and immunotherapies because the body’s natural defenses are compromised by persistent tumor immune evasion. These antibodies have the potential to be used as single agents in addition to being used in combinatorial approaches (e.g., with checkpoint inhibitors). These programs are based on the research conducted at Professor George Miller's laboratory and are exclusively licensed by PureTech from NYU School of Medicine. 

LYT-200 is a human IgG4 antibody directed against galectin-9, a global immunosuppressor. Galectin-9 exerts immunosuppression by binding to multiple partners and facilitating a tumor-permissive microenvironment. This antibody has shown excellent physical and functional properties, and exciting proof-of-concept data has been generated in both mouse and human cancer preclinical models.

MORE
LYT-210 (Immuno-oncology)
Anti-Delta-1 MAb
Solid tumors

LYT-210

PureTech is developing two first-in-class, fully human antibodies which are aimed at countering fundamental mechanisms of immunosuppression. PureTech’s therapeutic candidates are designed to address cancers that are suboptimally treated with currently available standard of care and immunotherapies because the body’s natural defenses are compromised by persistent tumor immune evasion. These antibodies have the potential to be used as single agents in addition to being used in combinatorial approaches (e.g., with checkpoint inhibitors). These programs are based on the research conducted at Professor George Miller's laboratory and are exclusively licensed by PureTech from NYU School of Medicine. 

LYT-210 is directed against immunosuppressive γδ T cells which are upregulated in multiple solid tumors and have a distinct phenotype as well as functional properties to make them uniquely targetable in cancer. This antibody has shown excellent physical and functional properties, and exciting proof-of-concept data has been generated in both mouse and human cancer preclinical models.

MORE
Lymphatic Targeting - Milk Exosomes

Lymphatic Targeting - Milk Exosomes

PureTech’s novel milk exosome-based technology may be uniquely positioned to facilitate the oral administration of complex payloads such as nucleic acids, peptides, and small molecules, by harnessing our growing understanding of the biology at the gut-immune interface. Milk exosomes represent a versatile engineerable platform to potentially resolve the long-standing challenge of oral bioavailability of macromolecules and complex small molecules. This technology is based on the research of Professor Ramesh Gupta at University of Louisville, and is exclusively licensed to PureTech. 

MORE
Lymphatic Targeting - Lipid Transport

Lymphatic Targeting - Lipid Transport

PureTech is developing a lymphatic targeting approach that leverages the body’s natural lipid transport mechanisms to substantially enhance the transport of compounds into the lymphatic system from an oral route. Nearly all dietary lipids (such as triglycerides) are absorbed from the small intestine into lymphatic vessels (lacteals), and these vessels transport lipids and immune cells to the mesenteric lymph nodes in the gut before entering systemic circulation. To access this absorption pathway, a triglyceride is reversibly attached to a drug of interest via a linker optimized to release the drug at the site of interest. This technology is based on the research of Professor Christopher Porter at Monash University in Australia and is exclusively licensed to PureTech.

MORE
Brain Lymphatics

Brain Lymphatics

PureTech is pursuing an approach to address neurodegenerative and neuroinflammatory conditions by harnessing the recently discovered lymphatic system in the brain. In July 2018, the foundational science that underlies PureTech’s internal CNS lymphatics technology was published as the cover story in the prestigious scientific journal Nature. The publication revealed that modulation of lymphatic function in the brain may prevent or delay diseases associated with aging, including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and age-associated cognitive decline. An additional Nature Neuroscience publication in September 2018 highlighted the key role of brain lymphatics in neuroinflammatory conditions such as multiple sclerosis. More recently, the role of meningeal lymphatics has been validated by other research groups as a key mediator in the clearance of macromolecules such as tau-related proteins and α-synuclein, from the CNS, which speaks to the potentially important role played by this system in tauopathies and Parkinson’s disease respectively. This technology is based on the research of Professor Jonathan Kipnis at the University of Virginia School of Medicine, and is exclusively licensed to PureTech.

MORE

Collaborating with Industry Leaders Across Our Affiliate and Internal R&D Pipelines

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche

CASE STUDIES

DISCOVERY REINVENTED

  • Aging related immune disorders
  • Gut/Immune Ecosystem
  • Severe and Chronic Mental Health